Erez Aminov - May 28, 2025 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)

Role
CEO and Chairman, Director
Signature
/s/ Erez Aminov
Stock symbol
TELO
Transactions as of
May 28, 2025
Transactions value $
$0
Form type
4
Date filed
5/30/2025, 08:00 PM
Previous filing
Feb 4, 2025
Next filing
Sep 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aminov Erez CEO and Chairman, Director C/O TELOMIR PHARMACEUTICALS, INC., 100 SE 2ND ST, SUITE 200 #1009, MIAMI, /s/ Erez Aminov 2025-05-30 0001986112

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TELO Non-Qualified Options Award $0 +2M $0.00 2M May 28, 2025 Common Stock 2M $2.10 Direct F1, F2
transaction TELO Restricted Stock Units (RSUs) Award $0 +400K $0.00 400K May 28, 2025 Common Stock 400K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025.
F2 The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant.
F3 Each restricted stock unit represents a right to receive one share of Issuer's common stock.
F4 The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant.
F5 Each restricted stock unit represents a right to receive one share of Issuer's common stock.